Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 243

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 243
---
 (15)Net income— — — — 73,016 73,016 Balance at March 31, 202546,784 $4 $481,361 $1 $(259,638)$221,728 

For the Three Months Ended March 31, 2024Stockholders' EquityCommon StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotalSharesPar ValueBalance at December 31, 202324,554 $2 $374,129 $27 $(268,963)$105,195 Share-based compensation expense— — 3,589 — — 3,589 Unrealized loss on investments, net of tax— — — (35)— (35)Net loss— — — — (18,289)(18,289)Balance at March 31, 202424,554 $2 $377,718 (8)$(287,252)$90,460 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

WHITEHAWK THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended March 31,20252024Cash flows from operating activities:Net income (loss)$73,016 $(18,289)Adjustments to reconcile net income (loss) to net cash used in operating activities:Share-based compensation expense1,680 3,589 Gain on sale of business(87,443)— Discount amortization on short-term investments19 (422)Non-cash interest expense— 58 Non-cash lease expense74 115 Depreciation expense57 50 Changes in operating assets and liabilities:Accounts receivable(1,000)555 Inventory170 490 Prepaid expenses and other current assets765 953 Other non-current assets114 138 Operating lease liabilities(89)(126)Accounts payable and accrued liabilities975 (6,764)Other liabilities(202)— Net cash used in operating activities(11,864)(19,653)Cash flows from investing activities:Proceeds from sale of business, net cash, cash equivalents, and restricted cash101,356 — Purchases of property and equipment(551)(739)Purchase of short-term investments— (7,646)Maturity of short-term investments14